Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients

Sponsor

Assiut University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05915676

Collaborator

(none)

100

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

To evaluate the frequency of LILRA3 in Ankylosing spondylitis and Axial psoriatic arthritis patients.
To investigate the association of LILRA3 with Ankylosing spondylitis and Axial psoriatic arthritis disease activity and severity.

Condition or Disease	Intervention/Treatment	Phase
Autoimmune Diseases	Diagnostic Test: Leukocyte Immunoglobulin-like receptors A3

Detailed Description

Axial spondyloarthritis (axSpA) is a complex inflammatory condition that affects the axial skeleton including the sacroiliac joints and the spine (1). It also affects peripheral joints and can be associated with extra-musculoskeletal manifestations including uveitis, psoriasis, and inflammatory bowel disease (1).

Axial spondyloarthritis include ankylosing spondylitis (AS), certain forms of psoriatic arthritis (PsA), reactive arthritis with axial involvement, and arthritis associated with inflammatory bowel disease (2).

The diagnosis of axSpA remains very challenging with years of delays attributed to several different factors. There is also a strong need to identify new serological biomarkers that can aid clinicians for diagnosis of axSpA.

Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.

Study Design

Study Type:

Observational

Anticipated Enrollment :

100 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Frequency Assessment of Leukocyte Immunoglobulin-like Receptors A3 In Ankylosing Spondylitis And Axial Psoriatic Arthritis Patients

Anticipated Study Start Date :

Jul 1, 2023

Anticipated Primary Completion Date :

Jun 1, 2024

Anticipated Study Completion Date :

Jul 30, 2024

Outcome Measures

Primary Outcome Measures

LILRA3 in AS and Axial psoriatic arthritis patients. [Baseline]
To evaluate the frequency of LILRA3 in Ankylosing spondylitis and Axial psoriatic arthritis patients.

Secondary Outcome Measures

Assosciation of LILRA3 with disease severity [Baseline]
To investigate the association of LILRA3 with Ankylosing spondylitis and Axial psoriatic arthritis disease activity and severity.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Inclusion Criteria:Adult AS and axPsA patients <18 years Who fulfilled the Assessment of SpondyloArthritis international Society (ASAS) criteria for axSpA.

Exclusion Criteria:1-patients less than 18 years old

2-Individuals with other autoimmune diseases

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Assiut University

Investigators

Study Chair: Zahraa Abou eleyoun, PHD, Assiut University

Study Documents (Full-Text)

None provided.

More Information

Publications

Ryu M, Chen Y, Qi J, Liu J, Fan Z, Nam G, Shi Y, Cheng H, Gao GF. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1/LILRB2: structural evidence. PLoS One. 2011 Apr 29;6(4):e19245. doi: 10.1371/journal.pone.0019245.

Responsible Party:

Alaa Adel Abdelmoez, Frequency Assessment of Leukocyte Immunoglobulin-like receptors A3 In Ankylosing Spondylitis And Axial Psoriatic Arthritis Patients, Assiut University

ClinicalTrials.gov Identifier:

NCT05915676

Other Study ID Numbers: